Translational Pharmacokinetic‐Pharmacodynamic Modeling and Efficacious Human Dose Prediction of <scp>DNDI</scp> ‐6148 for the Treatment of Cutaneous Leishmaniasis
, respectively. DNDI-6148 doses of 4.0 and 6.0 mg/kg once daily for 14 days were predicted to achieve 95% and 99% parasite reduction from baseline, respectively, in > 90% of simulated patients. This translational PK/PD modeling framework based on a murine infection model of cutaneous leishmaniasis effectively informs human dose selection by accounting for both PK and PD at the skin target site.
Authors
- Jadel M. Kratz (ORCID: https://orcid.org/0000-0002-7681-8234)
- Thomas P. C. Dorlo (ORCID: https://orcid.org/0000-0003-3076-8435)
- Jean‐Yves Gillon (ORCID: https://orcid.org/0000-0003-1467-0403)
- Byron Arana (ORCID: https://orcid.org/0000-0002-8407-7093)
- Charles E. Mowbray (ORCID: https://orcid.org/0000-0003-3538-8116)
- Wietse M. Schouten
- Katrien Van Bocxlaer
- Rasmus Hansen Henninger (ORCID: https://orcid.org/0009-0009-4129-3755)
Institutions
- Uppsala University (SE)
- Drugs for Neglected Diseases Initiative (CH)
- Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NL)
- University of York (GB)
- Hull York Medical School (GB)
Publication Details
- Journal
- Clinical and Translational Science
- Published
- 2026-04-01
- DOI
- https://doi.org/10.1111/cts.70535
- Primary Topic
- Research on Leishmaniasis Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00